Summary Monoclonal antibody SP-2 to the tumour-associated antigen 90K was generated by immunisation with conditioned medium of human breast cancer cells. We investigated whether circulating levels of 90K can influence the prognosis of patients with breast cancer. Serum samples were obtained from 425 patients with histologically proven breast cancer with no clinical evidence of disease after surgery (NED) and in 310 patients with metastatic disease. Serum 90K was determined by a new immunoradiometric assay (IRMA). Antigen levels in NED patients were elevated in 18.5% of cases, mean levels being higher than in healthy controls (P = 0.001). Among 375 evaluable patients, the 75-month overall survival for 90K-negative ( < 11 U ml-') and 90K-positive (>11 U ml-) patients was 78% and 53% respectively (P = 0.004 (Suter et al., 1989) . Biotinylation of SP-2 was carried out according to Guesdon et al. (1979) . After coating, the beads were washed extensively with 0.9% sodium chloride solution and incubated with biotinylated SP-2 (5fig ml-') at room temperature for 18 h. Coated beads were treated with an overcoating solution of bovine serum albumin (BSA) (2 mg ml-') for 1 h at room temperature, washed with distilled water and stored at room temperature until used. Beads treated in this fashion were stable for at least 6 months.
Summary Monoclonal antibody SP-2 to the tumour-associated antigen 90K was generated by immunisation with conditioned medium of human breast cancer cells. We investigated whether circulating levels of 90K can influence the prognosis of patients with breast cancer. Serum samples were obtained from 425 patients with histologically proven breast cancer with no clinical evidence of disease after surgery (NED) and in 310 patients with metastatic disease. Serum 90K was determined by a new immunoradiometric assay (IRMA). Antigen levels in NED patients were elevated in 18.5% of cases, mean levels being higher than in healthy controls (P = 0.001). Among 375 evaluable patients, the 75-month overall survival for 90K-negative ( < 11 U ml-') and 90K-positive (>11 U ml-) patients was 78% and 53% respectively (P = 0.004). The prognostic value of 90K appeared to be limited to patients with node-positive disease. Number of metastatic axillary lymph nodes and level of 90K antigen were the only independent variables for predicting overall survival. Patients with metastatic breast cancer had elevated 90K in 51.3% of cases. High 90K levels were significantly associated with the presence of metastases to liver, shorter disease-free interval and younger age. We conclude that an elevated 90K antigen level in serum is a predictor of poor prognosis in breast cancer.
Human neoplasms may express and release into the circulation a variety of substances collectively referred to as tumour markers. Serological analysis of these markers in cancer patients has been used extensively for diagnostic as well as predictive tests for cancer and metastases. To obtain monoclonal antibodies (MAbs) against circulating breast cancer markers, we immunised mice with proteins released into tissue culture fluid of human breast cancer cells (lacobelli et al., 1986) . One of the MAbs generated, SP-2, identified an antigen with a molecular weight of approximately 90,000 daltons which is expressed in more than 80% of breast cancer tissues, but not in non-cancerous normal mammary gland surrounding the cancer cells (lacobelli et al., 1986) . The MAb SP-2-reactive antigen, designated 90K, is present in human serum and is elevated in women with breast cancer (lacobelli et al., 1986 ). An enzyme-linked immunosorbent assay (ELISA) has been established with MAb SP-2 to detect circulating 90K antigen (lacobelli et al., 1988 (Iacobelli et al., 1988 (Suter et al., 1989) . Biotinylation of SP-2 was carried out according to Guesdon et al. (1979) . After coating, the beads were washed extensively with 0.9% sodium chloride solution and incubated with biotinylated SP-2 (5fig ml-') at room temperature for 18 h. Coated beads were treated with an overcoating solution of bovine serum albumin (BSA) (2 mg ml-') for 1 h at room temperature, washed with distilled water and stored at room temperature until used. Beads treated in this fashion were stable for at least 6 months.
With each assay, 200-jil aliquots of appropriately diluted samples or standards were incubated with SP-2-coated beads for 1 h at 37°C. The beads were washed with distilled water followed by the addition of 100ll of '25I-labelled SP-2 (approximately 50,000c.p.m.; specific activity 10 CifLg-1) in PBS, pH7.4, containing 5% BSA, 0.1mgml-' normal mouse IgG and 0.1 % sodium azide for an additional hour at 37'C. Beads were washed with distilled water and counted in a gamma-counter. (Kruskal & Wallis, 1952) . Correlations between 90K status (positive or negative) and other clinicopathological features were evaluated using the chi-square test. Survival was calculated from the day of first 90K measurement by the Kaplan-Meier (1958) method. Differences between curves were analysed using Mantel's log-rank test (Mantel, 1966) . The regression model of Cox (1972) was used to evaluate the predictive power of various prognostic factors in a multivariate manner. Statistical analyses were performed using the BMDP statistical package (BMDP Statistical Software, Los Angeles, CA, USA).
Results
Sera from 285 apparently healthy subjects (female blood donors) were assayed for 90K levels by IRMA (Table I ). The mean 90K serum level in this group was 5.6 ± 2.7 U ml'. The cut-off value of 90K was arbitrarily set at the mean plus 2 s.d. (11 U ml-') to define the positive rate. The serum level of 90K was not affected by sex, blood group and menstrual cycle (not shown). In addition, no influence of age could be detected when subjects were separated into age groups of 10 years (not shown). These results are in keeping with data of previous studies in which serum 90K was measured by ELISA (lacobelli et al., 1988) .
Serum 90K in NED breast cancer patients
We obtained serum samples from 425 patients with breast cancer apparently free of disease after surgery. These patients were followed up for a median of 62 months from study entry (range 2-75). During this period, 50 patients were lost to follow up. Overall, 90K levels were positive in 79 (18.5%) patients at the first assay of the marker (Table I ). The number of positive cases and the mean level (11.3 ± 8.3 U ml-') were significantly higher than in controls (P = 0.001). At Kaplan-Meier analysis, of the 375 patients for whom follow up data were available, 223 of 286 patients with initial 90K-negative sera (serum 90K levels < 11 U ml-') survived for 75 months, whereas those with 90K-positive (90K levels > 11 U ml-) sera had a significantly worse outcome (overall 75-month survival 78% vs 53%, Figure la) . When nodenegative and node-positive patient subpopulations were analysed separately, a correlation between poor prognosis and high value (>11 U ml-') of 90K was observed only for the latter (Figure lb and c) . No significant correlation was observed between 90K and disease-free survival in both node categories (not shown).
The interrelationship of various prognostic factors, including 90K serum level, with overall survival in patients with node-positive disease was evaluated. Multivariate analysis showed that the only independent factors for survival were the number of metastatic axillary lymph nodes at diagnosis (P = 0.001) and the initial 90K value (P = 0.005) (Table  III) .
In 36 patients, the 90K serum level was measured serially every 3-6 months for up to 48 months after primary breast surgery, focusing on its relationship with the occurrence of distant metastases (Figure 2 ). Nine patients (25%) were found to develop metastatic disease within 40 months after surgery, while the remaining 26 patients did not develop metastases until up to 48 months. In the group developing metastases, serum 90K was high (11.9 ± 6.7 U ml') before breast surgery and decreased thereafter. However, in eight of nine patients, the 90K level increased again at the time of metastases, reaching higher levels than before surgery. In three patients (as shown by an arrow in Figure 2 ), reelevation of the 90K level occurred before the clinical symptoms were manifested, and thereafter the diagnosis of metastases was confirmed radiographically. In contrast, in the 27 patients remaining disease free, the 90K level before surgery was relatively low (6.9 ± 3.8 U ml-') and remained within the normal range after surgery, with the exception of five patients who showed an increase above the cut-off during the investigation period. (90) aPatients with serum 90K levels >11 U ml-' were labelled as 90K
positive. NS, not significant. (Table IV) . High 90K levels were significantly correlated with metastatic liver involvement (P = 0.009), a disease-free interval of less than 12 months (P = 0.005) and an age of less than 50 years (P = 0.01). Also, there was a trend for patients with more than one metastatic site to have 036 more frequently increased 90K serum levels (P = 0.07, Table   IV ). that those patients with node-positive disease and 90K serum levels higher than the cut-off value (11 U ml-') had a shorter overall survival than patients with lower 90K levels, independent of other prognostic factors. In node-negative patients, P = 0.004 90K failed to predict clinical outcome. The reason for this is currently unclear. We also obtained evidence that 90K is able to detect early relapse during post-surgical follow-up. Indeed, (45) aPatients with serum 90K levels >11 U ml-' were labelled as 90K
positive. NS, not significant.
an elevation of 90K before confirmation of diagnosis by radiographic examination. This suggests that 90K is a strong indicator of tumour relapse. This would make it possible to select subgroups of patients most suited to receive more aggressive adjuvant treatment and/or a closer post-operative follow-up and suggests the importance of serial determinations of serum 90K for early detection of metastases. In this respect, it should be emphasised that the new 90K IRMA described in this article has proven to be easier to perform and more rapid and accurate than the previous ELISA. Determination of 90K in 425 breast cancer NED patients revealed supranormal 90K serum levels in 18.5% of cases. This figure is higher than the percentages of elevated values observed with CA 15-3 or CEA in the same category of patients (Ingersleben et al., 1987; Colomer et al., 1989) . High 90K levels in patients apparently free of disease could be considered as a sign of occult cancer. Although this point was not specifically addressed in our study, it is interesting to report that an elevation of 90K serum levels after administration of recombinant interferon a was associated with early relapse in NED cancer patients (Scambia et al., 1991; Natoli et al., 1993) .
Regarding advanced breast cancer, 90K seems to be related to a more severe course of the disease. Though only about one-half of patients with metastatic disease had supranormal 90K serum levels, a correlation was found with metastatic liver involvement, a shorter disease-free interval and a younger age. On the contrary, there was no clear correlation with number of metastatic sites. This suggests that circulating 90K levels may be influenced by other factors, such as the biological characteristics of the tumour itself and the ability of cancer cells to produce and secrete the antigen into the circulation. In this regard, we do not know whether the amount of 90K in serum reflects changes in synthesis or secretion of 90K from cancer cells. We are currently investigating the relationship between the expression of this antigen in cancer tissues by immunohistochemical staining and circulating serum levels. To date, we have been unable to demonstrate any correlation (unpublished data). Finally, although the original MAb SP-2 recognising 90K was raised against proteins released from breast cancer cells (Iacobelli et al., 1986) , we cannot exclude the possibility that a proportion of serum 90K may derive from other sources, such as liver, either directly or as a consequence of the metastatic involvement.
We have previously shown that 90K antigen is not related to other circulating breast cancer markers such as CA 15-3 and CEA (lacobelli et al., 1988) . Other tumour-associated antigens shown to be expressed by breast cancers with apparent molecular weight of approximately 90,000 daltons are likely to represent distinct molecules for the following reasons. The antigen recognised by MAb B6.2 (Kufe et al., 1983; Schlom et al., 1984 ) is a surface glycoprotein and therefore distinct from 90K, which is localised in the cytoplasm (lacobelli et al., 1988) . Moreover, in contrast to 90K, the MAb B.2-defined antigen is restricted to breast cancer cells. The antigen recognised by MAb 465.12S (Natali et al., 1982 ) is also a cell-surface glycoprotein and therefore distinct from 90K (Iacobelli et al., 1986) . The melanoma-associated antigen termed p97, gp87 or gp95 (Dippold et al., 1980; Brown et al., 1981; Liao et al., 1985) is a membrane protein that is structurally related to transferrin (Brown et al., 1982) . Another melanoma antigen, FD, is also a cell-surface glycoprotein whose expression is restricted to a very limited number of cells (Mattes et al., 1987) . Further, the antigen defined by MAb 3G2-C6 (Zhang & Lin, 1989 ) is a cellsurface component expressed in a significant number of bladder cancers but rarely present in breast cancers (Young et al., 1985) .
Finally, that 90K is distinct from other tumour markers is confirmed by our recent data showing that the protein has an amino-terminal sequence not previously described (lacobelli et al., 1993) .
In summary, we feel that the assay of 90K in serum may have clinical potential not only as a cancer monitoring test, but also as a prognostic factor.
